PGEN Company Profile and Key Details
Precigen
Price Chart
Stock Price Today
Precigen, Inc. (PGEN) stock surged +1.47%, trading at $4.14 on NASDAQ, up from the previous close of $4.08. The stock opened at $4.06, fluctuating between $4.03 and $4.14 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 04, 2026 | 4.06 | 4.14 | 4.03 | 4.14 | 2.26M |
| Apr 30, 2026 | 4.09 | 4.24 | 4.09 | 4.16 | 2.51M |
| Apr 29, 2026 | 3.96 | 4.20 | 3.92 | 4.12 | 2.9M |
| Apr 28, 2026 | 3.96 | 4.10 | 3.93 | 4.02 | 1.82M |
| Apr 27, 2026 | 4.10 | 4.24 | 3.96 | 3.96 | 2.8M |
| Apr 23, 2026 | 3.97 | 4.06 | 3.84 | 3.96 | 4.95M |
| Apr 22, 2026 | 4.02 | 4.05 | 3.91 | 3.96 | 1.64M |
| Apr 21, 2026 | 4.09 | 4.12 | 3.94 | 3.98 | 1.65M |
| Apr 20, 2026 | 3.99 | 4.30 | 3.98 | 4.11 | 3.67M |
| Apr 17, 2026 | 4.04 | 4.05 | 3.91 | 3.98 | 2.5M |
| Apr 16, 2026 | 3.92 | 3.96 | 3.80 | 3.95 | 2.35M |
| Apr 14, 2026 | 4.17 | 4.28 | 3.91 | 3.98 | 4.18M |
| Apr 13, 2026 | 4.16 | 4.26 | 4.10 | 4.17 | 1.7M |
| Apr 10, 2026 | 4.30 | 4.37 | 4.07 | 4.16 | 2.82M |
| Apr 09, 2026 | 4.06 | 4.30 | 4.02 | 4.27 | 2.58M |
| Apr 08, 2026 | 4.28 | 4.34 | 4.01 | 4.12 | 5.49M |
| Apr 07, 2026 | 4.11 | 4.20 | 3.95 | 4.12 | 2.7M |
| Apr 06, 2026 | 3.95 | 4.20 | 3.92 | 4.19 | 3.69M |
| Apr 02, 2026 | 3.86 | 4.03 | 3.75 | 3.94 | 5.43M |
| Apr 01, 2026 | 3.81 | 4.06 | 3.78 | 3.93 | 5.72M |
Contact Details
About Company
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Company Information
| Employees | 143 |
| Beta | 1.12 |
| Sales or Revenue | $6.23M |
| 5Y Sales Change% | -0.979% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Chief Financial Officer
Dr. Thomas D. Reed
Founder & Chief Science Officer
Mr. Steven Harasym
Vice President & Head of Investor Relations
Mr. Donald P. Lehr
Chief Legal Officer & Corporation Sec.
Dr. Helen Sabzevari MPH, Ph.D.
Pres, Chief Executive Officer & Director
Mr. Jeffrey Thomas Perez
Senior Vice President of Intellectual Property Affairs
Mr. Randal J. Kirk J.D.
Executive Chairman
Marie Rossi
Vice President of Communications
Mr. Rutul R. Shah
Chief Operating Officer
Dr. Thomas D. Reed Ph.D.
Founder & Chief Science Officer
Mr. Rob Russell
Vice President & Head of HR
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep